203 related articles for article (PubMed ID: 16818368)
1. CpG motifs to modulate innate and adaptive immune responses.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):125-34. PubMed ID: 16818368
[TBL] [Abstract][Full Text] [Related]
2. TLR9 in health and disease.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):155-81. PubMed ID: 16818370
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
4. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of immunostimulatory oligonucleotides.
Uhlmann E; Vollmer J
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
[TBL] [Abstract][Full Text] [Related]
7. Synthetic agonists of Toll-like receptors 7, 8 and 9.
Agrawal S; Kandimalla ER
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
[TBL] [Abstract][Full Text] [Related]
8. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of the innate immune responses in wild-derived inbred strains of mice.
Stephan K; Smirnova I; Jacque B; Poltorak A
Eur J Immunol; 2007 Jan; 37(1):212-23. PubMed ID: 17163447
[TBL] [Abstract][Full Text] [Related]
10. Innate immune recognition of, and regulation by, DNA.
Ishii KJ; Akira S
Trends Immunol; 2006 Nov; 27(11):525-32. PubMed ID: 16979939
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in immunostimulatory CpG oligonucleotides.
Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and characterization of equine Toll-like receptor 9.
Zhang YW; Davis EG; Blecha F; Wilkerson MJ
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):209-19. PubMed ID: 18462806
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory DNA as a vaccine adjuvant.
Higgins D; Marshall JD; Traquina P; Van Nest G; Livingston BD
Expert Rev Vaccines; 2007 Oct; 6(5):747-59. PubMed ID: 17931155
[TBL] [Abstract][Full Text] [Related]
16. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
Harandi AM; Holmgren J
Curr Opin Investig Drugs; 2004 Feb; 5(2):141-5. PubMed ID: 15043387
[TBL] [Abstract][Full Text] [Related]
17. Enhancing immunogenicity by CpG DNA.
Jiang W; Pisetsky DS
Curr Opin Mol Ther; 2003 Apr; 5(2):180-5. PubMed ID: 12772509
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant properties of CpG oligonucleotides in primates.
Verthelyi D
Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
[TBL] [Abstract][Full Text] [Related]
19. Characterization of three distinct CpG oligonucleotide classes which differ in ability to induce IFN alpha/beta activity and cell proliferation in Atlantic salmon (Salmo salar L.) leukocytes.
Strandskog G; Ellingsen T; Jørgensen JB
Dev Comp Immunol; 2007; 31(1):39-51. PubMed ID: 16890289
[TBL] [Abstract][Full Text] [Related]
20. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]